

Mark Gurnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/356842/publications.pdf>

Version: 2024-02-01

125
papers

8,272
citations

76326

40
h-index

49909

87
g-index

127
all docs

127
docs citations

127
times ranked

8286
citing authors

#	ARTICLE	IF	CITATIONS
1	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	2.9	7
2	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 47-58.	10.7	74
3	Long-term oncological outcomes after haemorrhagic apoplexy in pituitary adenoma managed operatively and non-operatively. <i>Acta Neurochirurgica</i> , 2022, 164, 1115.	1.7	5
4	Using very short answer errors to guide teaching. <i>Clinical Teacher</i> , 2022, , .	0.8	2
5	An approach to a patient with primary hyperparathyroidism and a suspected ectopic parathyroid adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	4
6	Black urine"alkaptonuria. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, , .	0.5	0
7	Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study. , 2022, , .		0
8	Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. <i>EJNMMI Research</i> , 2022, 12, 26.	2.5	4
9	Wilson Disease: Never Too Late . . . <i>American Journal of Medicine</i> , 2022, 135, e370-e371.	1.5	3
10	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. <i>Pituitary</i> , 2022, 25, 587-601.	2.9	9
11	11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. <i>Pituitary</i> , 2022, 25, 573-586.	2.9	7
12	Modern imaging in Cushing's disease. <i>Pituitary</i> , 2022, 25, 709-712.	2.9	10
13	Ablation Treatment Planning for Patients with Primary Aldosteronism. , 2022, , .		1
14	National inter-rater agreement of standardised simulated-patient-based assessments. <i>Medical Teacher</i> , 2021, 43, 341-346.	1.8	2
15	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 871-881.	5.6	65
16	New types of localization methods for adrenocorticotrophic hormone-dependent Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101513.	4.7	16
17	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.2	31
18	The influence of candidates' physical attributes on assessors' ratings in clinical practice. <i>Medical Teacher</i> , 2021, 43, 554-559.	1.8	3

#	ARTICLE	IF	CITATIONS
19	AST to ALT Ratio and Peripheral Arterial Disease in a Hypertensive Population—Is There a Link?. <i>Angiology</i> , 2021, 72, 905-907.	1.8	2
20	3D printing 18F radioactive phantoms for PET imaging. <i>EJNMMI Physics</i> , 2021, 8, 38.	2.7	9
21	Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. <i>Journal of Internal Medicine</i> , 2021, 290, 240-256.	6.0	18
22	Thinking differently — Students' cognitive processes when answering two different formats of written question. <i>Medical Teacher</i> , 2021, 43, 1-8.	1.8	10
23	Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas. <i>Journal of Nuclear Medicine</i> , 2021, 62, 57S-62S.	5.0	10
24	Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. <i>Pituitary</i> , 2021, 24, 839-853.	2.9	24
25	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. <i>Nature Genetics</i> , 2021, 53, 1360-1372.	21.4	37
26	Methods of 3D printing models of pituitary tumors. <i>3D Printing in Medicine</i> , 2021, 7, 24.	3.1	12
27	Functional imaging. , 2021, , 103-113.		1
28	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
29	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report. <i>New England Journal of Medicine</i> , 2021, 385, 1868-1880.	27.0	352
30	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
31	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	3.6	22
32	Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia. <i>Thyroid</i> , 2020, 30, 1681-1684.	4.5	3
33	Advances in the Imaging of Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 357-373.	3.2	20
34	A remarkable case of thyrotoxicosis initially caused by graves' disease followed by a probable TSHoma — a case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 133.	2.2	3
35	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	5.7	183
36	A safe approach to surgery for pituitary and skull base lesions during the COVID-19 pandemic. <i>Acta Neurochirurgica</i> , 2020, 162, 1509-1511.	1.7	22

#	ARTICLE	IF	CITATIONS
37	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. <i>Pituitary</i> , 2020, 23, 327-337.	2.9	49
38	Response to Letter to the Editor: “IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction”. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2315-e2316.	3.6	0
39	Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods. <i>European Journal of Endocrinology</i> , 2020, 182, 533-538.	3.7	14
40	Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. <i>Endocrine-Related Cancer</i> , 2020, 27, 361-373.	3.1	15
41	PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. <i>Neurosurgical Focus</i> , 2020, 48, E8.	2.3	19
42	Clinical Evaluation of ¹¹ C-Met-Avid Pituitary Lesions Using a ZTE-Based AC Method. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 504-508.	3.7	10
43	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. <i>Hypertension</i> , 2019, 74, 1152-1159.	2.7	15
44	Modern imaging of pituitary adenomas. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101278.	4.7	54
45	¹¹ C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. <i>Clinical Endocrinology</i> , 2019, 90, 670-679.	2.4	49
46	Comparing single-best-answer and very-short-answer questions for the assessment of applied medical knowledge in 20 UK medical schools: Cross-sectional study. <i>BMJ Open</i> , 2019, 9, e032550.	1.9	31
47	Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. <i>ERJ Open Research</i> , 2019, 5, 00009-2019.	2.6	36
48	Reduction in Total Radiation Exposure Using X-ray Image Guidance Illustrated in a Patient Receiving Pituitary Radiotherapy. <i>Clinical Oncology</i> , 2018, 30, 199-200.	1.4	0
49	Oncogenic osteomalacia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 421-422.	0.5	0
50	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	3.7	196
51	A journal for the modern era. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00001.	2.4	0
52	Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. <i>Seminars in Oncology</i> , 2018, 45, 151-155.	2.2	19
53	A novel IGSF1 mutation in a large Irish kindred highlights the need for familial screening in the IGSF1 deficiency syndrome. <i>Clinical Endocrinology</i> , 2018, 89, 813-823.	2.4	16
54	Adult female with symptomatic AVPR2-related nephrogenic syndrome of inappropriate antidiuresis (NSIAD). <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	5

#	ARTICLE	IF	CITATIONS
55	TSH-Secreting Pituitary Adenomas. , 2018, , 261-266.		0
56	Low DHEAS: A Sensitive and Specific Test for Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2718.	3.6	50
57	11C-metomidate PET-CT scanning can identify aldosterone-producing adenomas after unsuccessful lateralisation with CT/MRI and adrenal venous sampling. Journal of Human Hypertension, 2017, 31, 483-484.	2.2	11
58	Combining field work and laboratory work in the study of financial risk-taking. Hormones and Behavior, 2017, 92, 13-19.	2.1	10
59	Physiological and Pathological Roles in Human Adrenal of the Glomeruli-Defining Matrix Protein NPNT (Nephronectin). Hypertension, 2017, 69, 1207-1216.	2.7	19
60	NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)-Mediated Secretion of Aldosterone. Hypertension, 2017, 70, 357-364.	2.7	17
61	Variation in passing standards for graduation-level knowledge items at UK medical schools. Medical Education, 2017, 51, 612-620.	2.1	13
62	Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma. Clinical Case Reports (discontinued), 2017, 5, 1768-1771.	0.5	3
63	The use of ¹¹ carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma. BJR case Reports, 2017, 3, 20160098.	0.2	6
64	Time Dependence of Radiation-induced Hypothalamic-Pituitary Axis Dysfunction in Adults Treated for Non-pituitary, Intracranial Neoplasms. Clinical Oncology, 2017, 29, 34-41.	1.4	21
65	Is there an optimal preoperative management strategy for pheochromocytoma/paraganglioma?. Clinical Endocrinology, 2017, 86, 163-167.	2.4	33
66	Applying physical science techniques and CERN technology to an unsolved problem in radiation treatment for cancer: the multidisciplinary 'VoxTox' research programme. CERN IdeaSquare Journal of Experimental Innovation, 2017, 1, 3-12.	2.0	11
67	Gestational pituitary apoplexy. Indian Journal of Endocrinology and Metabolism, 2017, 21, 484.	0.4	6
68	Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT. Diagnostics, 2016, 6, 42.	2.6	21
69	Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. Clinical Endocrinology, 2016, 85, 306-312.	2.4	19
70	Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology, 2016, 84, 799-808.	2.4	149
71	Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy. Lancet Diabetes and Endocrinology, the, 2016, 4, 1050.	11.4	23
72	Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. European Journal of Endocrinology, 2016, 175, 485-498.	3.7	41

#	ARTICLE	IF	CITATIONS
73	Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. <i>Endocrine</i> , 2016, 54, 778-787.	2.3	15
74	EP-1129: Pre and post-irradiation hypothalamic-pituitary axis dysfunction in adults treated for brain tumours. <i>Radiotherapy and Oncology</i> , 2016, 119, S541.	0.6	0
75	Interceptive Ability Predicts Survival on a London Trading Floor. <i>Scientific Reports</i> , 2016, 6, 32986.	3.3	79
76	Order effects in high stakes undergraduate examinations: an analysis of 5 years of administrative data in one UK medical school. <i>BMJ Open</i> , 2016, 6, e012541.	1.9	2
77	Familial Adrenocortical Carcinoma in Association With Lynch Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2269-2272.	3.6	27
78	Clinical prevalence and outcome impact of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis. <i>Pituitary</i> , 2016, 19, 522-535.	2.9	23
79	A Novel Thyrotropin-Releasing Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 847-851.	3.6	25
80	Needle(s) in the Haystack – Synchronous Multifocal Tumor-Induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 390-393.	3.6	11
81	Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 75-85.	2.5	57
82	Nuclear imaging in the diagnosis of primary aldosteronism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 150-156.	2.3	34
83	Hypopituitarism, pulmonary infiltration and a spontaneously resolving occipital mass. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 147-149.	0.5	0
84	A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M107-M120.	3.7	73
85	Pregnancy, Primary Aldosteronism, and Adrenal <i>CTNNB1</i> Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 1429-1436.	27.0	123
86	Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4146-4154.	3.6	176
87	A Novel Albumin Gene Mutation (R222I) in Familial Dysalbuminemic Hyperthyroxinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1381-E1386.	3.6	28
88	Cortisol shifts financial risk preferences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3608-3613.	7.1	200
89	Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR) _{β1} and TR _{β2} : clinical, biochemical, and genetic analyses of three related patients. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 619-626.	11.4	100
90	An Adult Female With Resistance to Thyroid Hormone Mediated by Defective Thyroid Hormone Receptor β_2 . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4254-4261.	3.6	116

#	ARTICLE	IF	CITATIONS
91	A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1040-1050.	3.6	120
92	Pitfalls in the measurement and interpretation of thyroid function tests. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 745-762.	4.7	216
93	A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. <i>Clinical Endocrinology</i> , 2013, 78, 424-430.	2.4	28
94	More than just morning sickness. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 1123-1125.	0.5	2
95	How to interpret thyroid function tests. <i>Clinical Medicine</i> , 2013, 13, 282-286.	1.9	28
96	A Mutation in the Thyroid Hormone Receptor Alpha Gene. <i>New England Journal of Medicine</i> , 2012, 366, 243-249.	27.0	340
97	Evaluation of the Sensitivity and Specificity of ¹¹ C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 100-109.	3.6	203
98	Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. <i>Pituitary</i> , 2012, 15, 276-287.	2.9	54
99	What should be done when thyroid function tests do not make sense?. <i>Clinical Endocrinology</i> , 2011, 74, 673-678.	2.4	62
100	Increased Prevalence of Gallbladder Polyps in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1120-E1125.	3.6	16
101	Hypotension, polyuria and a cardiac arrest. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 437-438.	0.5	1
102	Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 4220-4235.	8.2	268
103	Maternal Isodisomy for Chromosome 9 Causing Homozygosity for a Novel FOXE1 Mutation in Syndromic Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4031-4036.	3.6	28
104	Resistance to Thyroid Hormone. , 2010, , 1745-1759.		7
105	Second-to-fourth digit ratio predicts success among high-frequency financial traders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 623-628.	7.1	297
106	Functional implications of genetic variation in human PPAR β . <i>Trends in Endocrinology and Metabolism</i> , 2009, 20, 380-387.	7.1	88
107	The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative pheochromocytoma. <i>European Journal of Endocrinology</i> , 2007, 157, 533-537.	3.7	42
108	Striking the Right Balance™ in Targeting PPAR β in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. <i>PPAR Research</i> , 2007, 2007, 1-14.	2.4	22

#	ARTICLE	IF	CITATIONS
109	Non-DNA binding, dominant-negative, human PPAR β mutations cause lipodystrophic insulin resistance. <i>Cell Metabolism</i> , 2006, 4, 303-311.	16.2	164
110	Elevated Plasma Adiponectin in Humans with Genetically Defective Insulin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3219-3223.	3.6	127
111	Peroxisome proliferator-activated receptor β and the regulation of adipocyte function: lessons from human genetic studies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2005, 19, 501-523.	4.7	64
112	Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors. <i>Essays in Biochemistry</i> , 2004, 40, 169-189.	4.7	19
113	PPAR β and metabolism: insights from the study of human genetic variants. <i>Clinical Endocrinology</i> , 2003, 59, 267-277.	2.4	78
114	The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor β and Its Therapeutic Modulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2412-2421.	3.6	167
115	Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor- β . <i>Diabetes</i> , 2003, 52, 910-917.	0.6	412
116	Molecular Characterisation of Dominant Negative Mutations in Human Ppar β . <i>Clinical Science</i> , 2002, 102, 1P-1P.	0.0	0
117	Digenic inheritance of severe insulin resistance in a human pedigree. <i>Nature Genetics</i> , 2002, 31, 379-384.	21.4	134
118	A Dominant-negative Peroxisome Proliferator-activated Receptor β (PPAR β) Mutant Is a Constitutive Repressor and Inhibits PPAR β -mediated Adipogenesis. <i>Journal of Biological Chemistry</i> , 2000, 275, 5754-5759.	3.4	249
119	Three Novel Mutations at Serine 314 in the Thyroid Hormone β Receptor Differentially Impair Ligand Binding in the Syndrome of Resistance to Thyroid Hormone ¹ . <i>Endocrinology</i> , 1999, 140, 5901-5906.	2.8	9
120	Dominant negative mutations in human PPAR β associated with severe insulin resistance, diabetes mellitus and hypertension. <i>Nature</i> , 1999, 402, 880-883.	27.8	1,286
121	A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. <i>EMBO Journal</i> , 1998, 17, 4760-4770.	7.8	130
122	Reversible Pituitary Enlargement in the Syndrome of Resistance to Thyroid Hormone. <i>Thyroid</i> , 1998, 8, 679-682.	4.5	37
123	Identification and characterization of a novel de novo mutation (L346V) in the thyroid hormone receptor beta gene in a family with generalized thyroid hormone resistance. <i>European Journal of Endocrinology</i> , 1997, 137, 370-376.	3.7	9
124	Extended TSS (guided by ¹¹ C-methionine PET + MRI (Met-PET/MRCR)) can be an effective treatment option for patients with persistent acromegaly due to previously deemed unresectable lateral disease. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
125	The influence of candidatesâ€™ physical attributes on patient ratings in simulated assessments of clinical practice. <i>Medical Teacher</i> , 0, , 1-6.	1.8	0